Topical Cannabinoids for the Management of Psoriasis Vulgaris
Authors Adam J. Friedman MD, Kimia Momeni BS, and Mikhail Kogan MD present a case of a young man with psoriasis managed with topical cannabinoids.
Introduction
The interest in use of medical cannabis for chronic dermatologic conditions such as psoriasis, eczema, and acne has been growing mostly owing to rapidly emerging decriminalization across the country and impressive commercially driven popu …
Authors Adam J. Friedman MD, Kimia Momeni BS, and Mikhail Kogan MD present a case of a young man with psoriasis managed with topical cannabinoids.
Introduction
The interest in use of medical cannabis for chronic dermatologic conditions such as psoriasis, eczema, and acne has been growing mostly owing to rapidly emerging decriminalization across the country and impressive commercially driven popu … Continue reading "Topical Cannabinoids for the Management of Psoriasis Vulgaris"
BACKGROUND
The upper lateral cheek bears unique and distinct local characteristics that are key features in facial aesthetics and functionality. Its main landmarks are the lower eyelid, the lateral canthus, and the temporal hairline. When contemplating treatment options for defects in this area, the surgeon should take into consideration the possible effects of the reconstructive method on the pr … 
Pediatric lichen planopilaris (LPP) is a clinical variant of lichen planus (LP) that can lead to scarring hair loss without prompt intervention. While various therapies exist, intralesional and topical corticosteroids remain the mainstay of treatment in pediatric LPP. Refractory cases may require systemic therapies, selection of which may prove challenging due to the lack of data regarding pediatr … 
JDD authors Samuel S. Kassirer BA, Robert H. Gotkin MD, and Deborah S. Sarnoff MD present the first reported case of rhinophyma in a 62-year-old Fitzpatrick V female patient who was successfully treated with one session of fractional CO2 laser resurfacing. This case highlights the successful use of the fractional CO2 laser to treat rhinophyma in darker skin types (Fitzpatrick IV–VI) and undersco … 
INTRODUCTION
Palbociclib is one of three new small-molecule inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for use in the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (Her2-) advanced or metastatic breast cancer. CDK4/6 inhibitors have a good overall safety profile but reported side effects include cytopenias, diarrhea, QTc pr … 